[关键词]
[摘要]
新型冠状病毒肺炎(COVID-19),2019年12月始发于我国湖北省武汉市,随后迅速传播至国内大部分省份和地区,甚至波及国外多个国家。COVID-19具有流行性广、传染性强、发病急骤和病情危重等特点。面对这场疫情,全国各地迅速掀起抗击COVID-19的高峰,但短期内尚未研发出治疗COVID-19的特效药物。近期,多家医院在运用化学药的基础上联合中医药治疗,临床效果显著,证实了中药具有抗病毒的作用。大量的药理学和临床研究证实,苦参具有显著的抗病毒作用。从多个路径阐述苦参抗冠状病毒作用的可能相关机制,如通过I型干扰素、核转录因子-κB(NF-κB)信号通路、细胞外信号调节激酶(ERK)信号通路、磷脂酰肌醇-3-羟激酶(PI3K)/蛋白激酶B(Akt)信号通路、苦参碱类生物碱等途径,拟为COVID-19的临床治疗和相关药物研发提供参考。
[Key word]
[Abstract]
The coronavirus disease 2019 (COVID-19), originated in Wuhan city, Hubei Province, China in December 2019, and then quickly spread to most provinces and regions in China and even spread to many countries abroad. COVID-19 is characterized by wide epidemic, strong infectivity, rapid onset and critical condition. In the face of this epidemic, all parts of the country quickly set off a peak in the fight against COVID-19, but no effective drug for COVID-19 has been developed in the short term. Recently, many hospitals have combined traditional Chinese medicine with western medicine in treatment, and the clinical effect is remarkable, which proves the antiviral effect of traditional Chinese medicine. A large number of pharmacological and clinical studies have proved that the Chinese materia medica S. flavescens has significant antiviral effect. In this paper, the mechanism of anti-coronavirus effect of S. flavescens is expounded from multiple pathways, such as type I interferon, NF-κB signal pathway, ERK signal pathway, PI3K/Akt signal pathway and matrine alkaloids, etc. It is intended to provide reference for clinical treatment of coronavirus infection pneumonia and research and development of related drugs of S. flavescens.
[中图分类号]
R285
[基金项目]
国家中医药管理局——全国中医药创新骨干人才培训项目(国中医药人教函[2019]128号)